Related Experiment Video

Updated: May 2, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic

Karen W L Yee1, John M Storring, Rena Buckstein

  • 1Princess Margaret Phase II Consortium , Toronto, Ontario , Canada.

Leukemia & Lymphoma
|March 12, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Experiment Videos

Last Updated: May 2, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

Frailty assessment in ovarian cancer: a systematic review of measurement definitions, methods, and clinical implications.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Comparative analysis of ovarian cancer tumor-infiltrating T cells with those in melanoma and before and after PD-1 blockade.

Cancer research communications·2026

The evolving role of immunotherapy in ovarian cancer.

Cancer·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.

Current oncology (Toronto, Ont.)·2026

Controversies in the Management of AML in Older Patients: A Canadian Perspective.

Current oncology (Toronto, Ont.)·2026

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

Leukemia & lymphoma·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026

Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.

Leukemia & lymphoma·2026

Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study.

Leukemia & lymphoma·2026

Emerging drug profile: bexobrutideg.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us